A Retrospective Study of the Role of Thiazolidinediones to Reduce the Incidence of Atrial Arrhythmias
NCT ID: NCT00321204
Last Updated: 2014-04-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
600 participants
OBSERVATIONAL
2005-12-31
2007-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Retrospective Analysis of the Use of ACE-inhibitors and Angiotensin Receptor Blockers
NCT00321945
Effect of Ischemic Preconditioning on Atrial Fibrillation After Electrocardioversion
NCT05342220
A Retrospective Analysis of the Predictive Potential of Pre-operative
NCT00321282
Prevention of Atrial Fibrillation Following Esophagectomy
NCT00420017
Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery
NCT00127712
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cardiac surgery is associated with many perioperative complications, including supraventricular arrhythmias.(1-4) Atrial fibrillation occurs in 15 to 40% of patients after coronary artery bypass grafting (CABG) and up to 60% after CABG and valve repair. It can lead to significant complications such as stroke, prolonged hospitalizations, increasing mortality and morbidity.(1;5)
Post-operative atrial arrhythmias seem to be related to the degree of inflammation and oxidative stress induced during surgery.(2-4) Our group and others have shown that atrial arrhythmias are associated with increased oxidative stress.(6-10) Moreover, increased oxidative stress associated with angiotensin II-mediated NADPH oxidase activation leads to electrical abnormalities likely to propagate arrhythmias.(11;12)
Thiazolidinediones (TZDs) are antidiabetic agents that enhance insulin sensitivity through activating peroxisome proliferators-activated receptor (PPAR) gamma. Beside their glucose lowering effects, TZDs are shown to exhibit anti-inflammatory and antioxidant properties.(13-17)
2.0 Objectives
Based on the discussion above, we hypothesize that pre-operative use of TZDs will decrease post-operative AF or Aflut incidence. This study will be a retrospective cohort analysis of all patients that underwent elective cardiac surgeries between 2000-2005 at Emory University Hospital, Crawford Long Hospital, or the Atlanta Veterans Affairs Medical Center to evaluate the relationship of pre-operative TZD use to the incidence of post-operative atrial arrhythmias.. This study is undertaken in preparation for a funding proposal for a prospective trial.
3.0 Patient Selection
3.1 Eligibility criteria:
1\. All patients that patients who underwent elective cardiac surgery in the Emory University Hospital, Crawford Long Hospital, or the VA Medical Center between 2000-2005.
3.2 Ineligibility criteria:
1. Emergent operations.
2. The presence of AF or Aflut at the time of surgery.
3. Patients without adequate documentation of atrial rhythm following surgery.
4. New York Heart Association (NYHA) class IV heart failure at the time of surgery.
5. Hyperthyroidism
6. Implanted devices for designed for active management of atrial arrhythmias by pacing or defibrillation
7. Known illicit drug use
8. Known ethanol abuse
9. Electrophysiological ablation for atrial tachycardia within 6 months of the operation.
4.0 Registration and randomization: none
5.0 Therapy: none
6.0 Pathology: none
7.0 Patient assessment: none
8.0 Data collection: Data will be collected from review of the patient's hospital charts, from telemetry recordings, and ECGs to document the presence or absence of AF or Aflut during the hospital admission for cardiac surgery. The presence or absence of atrial fibrillation will be diagnosed on the basis of an electrocardiographic recording and confirmed by a cardiologist. Demographic data collected will include: age, race, sex, body mass index, blood pressure, NYHA classification, Killip classification, and the history of previous myocardial infarction, hypertension, diabetes, smoking, alcohol use, antiarrhythmic drug use, presence and type of pacemaker if any, history of AF or Aflut, previous cardioversions, type of operation, and length of operation. Patients enrolled in this study will be given unique study numbers. No follow up data will be required from patients.
9.0 Statistical considerations: This study design is a retrospective chart review of a cohort of patients undergoing cardiac surgery to determine if there is an association between pre-operative TZD use and the incidence of post-operative atrial fibrillation or Aflut. The null hypothesis is that there is no association between the preoperative use of TZDs and postoperative AF and Aflut. Within the cohort, those patients with AF or Aflut will be compared to those without these atrial arrhythmias in the post-operative period. Baseline data for the two groups will be expressed as mean ± standard deviation for continuous variables, and frequencies for categorical variables. Differences in baseline characteristics between the groups will be examined by use of Fisher exact and Mann-Whitney tests for categorical and continuous variables, respectively. Quantification of any association between pre-operative TZD and the presence of atrial fibrillation will modeled by logistical regression analysis after adjusting for other variables that may affect arrhythmia frequency.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TZD reducing the incidence of atrial arrhythmias
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Emory University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Samuel C. Dudley, Jr.
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Samuel C. Dudley, Jr., MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Veteran Administration Medical Center/Emory University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Emory University Hospital
Atlanta, Georgia, United States
Emory Crawford Long Hospital
Atlanta, Georgia, United States
Veteran Administration Medical Center
Decatur, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1308-2005
Identifier Type: OTHER
Identifier Source: secondary_id
IRB00002175
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.